Morphosys makes equity-linked debut with €325m convert

GLOBALCAPITAL INTERNATIONAL LIMITED, a company

incorporated in England and Wales (company number 15236213),

having its registered office at 4 Bouverie Street, London, UK, EC4Y 8AX

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions

Cookies Settings
Equity
Equity-Linked

Morphosys makes equity-linked debut with €325m convert

Aidan Gregory
October 13, 2020 04:30 PM
Morphysis_PA_575_375
Juliane Bengsch preparing probes for an analysis with a mass spectrometer in a biochemical lab of the biotech company Centogene at the Biomedical Research Centre in Rostock, Germany, 17 August 2016. The company founded ten years ago employs more than 300 international workers, mainly for the diagnosis of rare hereditary diseases. On 23 August 2016, the cornerstone for the new company headquarters at the harbour of Rostock will be layed. PHOTO: BERND WUESTNECK/dpa | Bernd Wüstneck/DPA/PA Images

Morphosys, the German biotech company, has tapped the equity-linked market with a new €325m convertible bond, adding to the flood of issuance from the sector during the pandemic.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Topics

JP MorganGermanyHealth and BiotechEquityEuropeEMEASRIGoldman SachsEquity-Linked
AG
Aidan Gregory
Gift this article